AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 4064532 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (control)
Number of subjects: 114
Study 31830962 — intervention group
Group type: EXPERIMENTAL
Intervention: Biased vignettes (patients with schizophrenia or free care recipients)
Number of subjects: 207
Study 31830962 — intervention group
Group type: COMPARATOR
Intervention: Neutral vignettes (no additional patient information)
Number of subjects: 207
Study 28419778 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 600 mg formulation
Number of subjects: 0
Study 28419778 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 3 × 400 mg and 2 × 600 mg dosage forms
Number of subjects: 0
Study 28419778 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 2 × 600 mg formulation
Number of subjects: 0
Study 28419778 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 1200 mg
Number of subjects: 0
Study 28419778 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir multiple doses
Number of subjects: 0
Study 27192633 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight lifting intervention
Number of subjects: 281
Study 24119859 — intervention group
Group type: EXPERIMENTAL
Intervention: Humor therapy intervention provided by ElderClowns for 2-hour sessions, 9-12 times over 12 weeks.
Number of subjects: 189
Study 24119859 — intervention group
Group type: EXPERIMENTAL
Intervention: Humor therapy intervention
Number of subjects: 189
Study 22249997 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecosystem Focused Therapy (EFT)
Number of subjects: 24
Study 22249997 — intervention group
Group type: COMPARATOR
Intervention: Education on Stroke and Depression
Number of subjects: 24
Study 20165744 — intervention group
Group type: EXPERIMENTAL
Intervention: OFD+EMP
Number of subjects: 10
Study 20165744 — intervention group
Group type: COMPARATOR
Intervention: OFD
Number of subjects: 10
Study 18062519 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol mixed with 2cc of a solution containing phenylephrine 100 microg/cc (total 100 microg)
Number of subjects: 135
Study 18062519 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol mixed with 2cc of a solution containing phenylephrine 50 microg/cc (total 50 microg)
Number of subjects: 135
Study 18062519 — intervention group
Group type: COMPARATOR
Intervention: Propofol mixed with 2cc of 0.9% normal saline
Number of subjects: 135
Study 16173386 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined preventive-operative method including ART-fissure sealant/restoration and fluoride varnish application (test group)
Number of subjects: 27
Study 16173386 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 27
Study 16173386 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined preventive-operative method (test group)
Number of subjects: 27
Study 12068252 — intervention group
Group type: COMPARATOR
Intervention: Clinical routine alone
Number of subjects: 705
Study 12068252 — intervention group
Group type: EXPERIMENTAL
Intervention: CAGE questionnaire added
Number of subjects: 705
Study 12068252 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of GGT
Number of subjects: 705
Study 12068252 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of CDT
Number of subjects: 705
Study 12068252 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of all tests
Number of subjects: 705
Study 10913815 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery
Number of subjects: 464
Study 10913815 — intervention group
Group type: COMPARATOR
Intervention: Saphenous vein
Number of subjects: 464
Study 8873695 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg benazepril
Number of subjects: 103
Study 8873695 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg nicardipine
Number of subjects: 103
Study 8873695 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo run-in period)
Number of subjects: 103
Study 1742901 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin, 150 mg 4 times daily for 10 days
Number of subjects: 54
Study 1742901 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic treatment (Control)
Number of subjects: 54
Study 6743780 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 10
Study 6743780 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimipramine (50 mg)
Number of subjects: 10
Study 6743780 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg) + Trimipramine (50 mg)
Number of subjects: 10
Study 31404936 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training for 12 weeks
Number of subjects: 42
Study 31404936 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued own training methods)
Number of subjects: 42
Study 28870242 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative wound irrigation with 0.04% polyhexanide (PHX) solution
Number of subjects: 540
Study 28870242 — intervention group
Group type: COMPARATOR
Intervention: No irrigation (control group)
Number of subjects: 540
Study 28870242 — intervention group
Group type: COMPARATOR
Intervention: Saline irrigation (control group)
Number of subjects: 540
Study 26152221 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin intensive therapy
Number of subjects: 64
Study 26152221 — intervention group
Group type: COMPARATOR
Intervention: Control group with continuation of pre‐CR antidiabetic treatment
Number of subjects: 64
Study 26152221 — intervention group
Group type: EXPERIMENTAL
Intervention: Good glycemic control (final fructosamine level below median)
Number of subjects: 64
Study 26152221 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor glycemic control (final fructosamine level above median)
Number of subjects: 64
Study 22921159 — intervention group
Group type: EXPERIMENTAL
Intervention: Health information package (validated planned educational programme with visual aids and iron supplementation)
Number of subjects: 225
Study 22921159 — intervention group
Group type: COMPARATOR
Intervention: Control group A (iron supplementation only)
Number of subjects: 225
Study 22921159 — intervention group
Group type: COMPARATOR
Intervention: Control group B (iron supplementation only)
Number of subjects: 225
Study 21272979 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous graft
Number of subjects: 26
Study 21272979 — intervention group
Group type: COMPARATOR
Intervention: Medpor
Number of subjects: 26
Study 18481722 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved thunder-fire miraculous needle
Number of subjects: 117
Study 18481722 — intervention group
Group type: COMPARATOR
Intervention: Pressing and moxibustion at Baihui (GV 20)
Number of subjects: 117
Study 16290094 — intervention group
Group type: EXPERIMENTAL
Intervention: GP educational outreach visiting
Number of subjects: 461
Study 16290094 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured patient and caregiver educational outreach visiting
Number of subjects: 461
Study 16290094 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated palliative care model of case conferencing
Number of subjects: 461
Study 16290094 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 461
Study 16290094 — intervention group
Group type: COMPARATOR
Intervention: Standard model of palliative care
Number of subjects: 461
Study 15567112 — intervention group
Group type: EXPERIMENTAL
Intervention: Night Eating Syndrome Questionnaire (NESQ)
Number of subjects: 0
Study 15567112 — intervention group
Group type: EXPERIMENTAL
Intervention: Night eating screening question
Number of subjects: 0
Study 15567112 — intervention group
Group type: COMPARATOR
Intervention: Treatment outcomes (adherence and weight loss)
Number of subjects: 0
Study 11068858 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x weekly narrow-band UVB treatment
Number of subjects: 69
Study 11068858 — intervention group
Group type: COMPARATOR
Intervention: 4 x weekly narrow-band UVB treatment
Number of subjects: 69
Study 11068858 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 69
Study 9313738 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound imaging
Number of subjects: 20
Study 9313738 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography (CT)
Number of subjects: 20
Study 8329785 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavored Colestid Granules in water
Number of subjects: 72
Study 8329785 — intervention group
Group type: COMPARATOR
Intervention: Questran Light in orange juice
Number of subjects: 72
Study 2439786 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg bisoprolol
Number of subjects: 12
Study 2439786 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg bisoprolol
Number of subjects: 12
Study 2439786 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg bisoprolol
Number of subjects: 12
Study 2439786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2439786 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (all doses)
Number of subjects: 12
Study 2439786 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (20 mg)
Number of subjects: 12
Study 2439786 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (10 mg and 20 mg)
Number of subjects: 12
Study 2738457 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory Integrative Therapy (SIT) program
Number of subjects: 55
Study 2738457 — intervention group
Group type: COMPARATOR
Intervention: Parallel physical education program
Number of subjects: 55
Study 2738457 — intervention group
Group type: COMPARATOR
Intervention: No-treatment condition
Number of subjects: 55
Study 31740348 — intervention group
Group type: EXPERIMENTAL
Intervention: Doravirine (100 mg per day)
Number of subjects: 769
Study 31740348 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted darunavir (100 mg ritonavir and 800 mg darunavir per day)
Number of subjects: 769
Study 31740348 — intervention group
Group type: EXPERIMENTAL
Intervention: Doravirine
Number of subjects: 769
Study 31740348 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted darunavir
Number of subjects: 769
Study 29843517 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional and educational stroke DVD intervention over six weeks
Number of subjects: 66
Study 29843517 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 66
Study 27627647 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea gargling
Number of subjects: 747
Study 27627647 — intervention group
Group type: COMPARATOR
Intervention: Water gargling (control)
Number of subjects: 747
Study 26165919 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural suicide prevention (CBSP) therapy
Number of subjects: 62
Study 26165919 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 62
Study 23943299 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy (HT)
Number of subjects: 228
Study 23943299 — intervention group
Group type: COMPARATOR
Intervention: Deferred hormonal therapy (D(HT))
Number of subjects: 228
Study 23943299 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CHT)
Number of subjects: 228
Study 21930653 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (no AF recurrences during the 3-month postablation period)
Number of subjects: 286
Study 21930653 — intervention group
Group type: COMPARATOR
Intervention: Group 3 (treated only with antiarrhythmic drugs for 6 weeks)
Number of subjects: 286
Study 21930653 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4 (treated according to the onset mechanism of AF recurrences)
Number of subjects: 286
Study 18985146 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment (desipramine or fluoxetine) for 8 weeks
Number of subjects: 0
Study 18985146 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 16870913 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (20 ppm, decreasing concentrations for a minimum of 24 days)
Number of subjects: 582
Study 16870913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 582
Study 16870913 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 582
Study 15630774 — intervention group
Group type: EXPERIMENTAL
Intervention: One-on-one teaching
Number of subjects: 67
Study 15630774 — intervention group
Group type: EXPERIMENTAL
Intervention: Group teaching
Number of subjects: 67
Study 15630774 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study 11377900 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dorzolamide-timolol combination
Number of subjects: 30
Study 11377900 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost
Number of subjects: 30
Study 9243107 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 17 beta-estradiol for 6 weeks
Number of subjects: 40
Study 8500516 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (n = 34)
Number of subjects: 51
Study 8500516 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 17)
Number of subjects: 51
Study 3448453 — intervention group
Group type: EXPERIMENTAL
Intervention: Microencapsulated formulation (C)
Number of subjects: 0
Study 3448453 — intervention group
Group type: COMPARATOR
Intervention: Highly buffered formulation (A)
Number of subjects: 0
Study 3448453 — intervention group
Group type: COMPARATOR
Intervention: Cytoprotective formulation (B)
Number of subjects: 0
Study 3448453 — intervention group
Group type: COMPARATOR
Intervention: Plain tablet formulation (D)
Number of subjects: 0
Study 31669966 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐fidelity simulator
Number of subjects: 72
Study 31669966 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching method
Number of subjects: 72
Study 30224402 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults living with HIV
Number of subjects: 84
Study 30224402 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing depressive scores in adults living with HIV
Number of subjects: 84
Study 30224402 — intervention group
Group type: COMPARATOR
Intervention: Community controls
Number of subjects: 84
Study 27565270 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS + LABA treatment
Number of subjects: 0
Study 27565270 — intervention group
Group type: COMPARATOR
Intervention: ICS + LTRA treatment
Number of subjects: 0
Study 25335330 — intervention group
Group type: EXPERIMENTAL
Intervention: Yishen Jiejing Decoction (YJD), 50 mL, twice a day for one month
Number of subjects: 60
Study 25335330 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation training and therapeutics
Number of subjects: 60
Study 23050578 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led empowerment-based intervention (eight weekly sessions including lifestyle modification education, empowerment group discussions, and exercise training)
Number of subjects: 52
Study 23050578 — intervention group
Group type: COMPARATOR
Intervention: Standard hypertension care (control group)
Number of subjects: 52
Study 20444135 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovision correction contact lenses
Number of subjects: 11
Study 20444135 — intervention group
Group type: COMPARATOR
Intervention: Distance correction contact lenses
Number of subjects: 11
Study 18716496 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with low back pain
Number of subjects: 1342
Study 18716496 — intervention group
Group type: COMPARATOR
Intervention: Healthcare services utilization
Number of subjects: 1342
Study 16758849 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic-hyperoncotic solution
Number of subjects: 40
Study 16758849 — intervention group
Group type: COMPARATOR
Intervention: Isotonic solution
Number of subjects: 40
Study 12638028 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrates (HC) diet (65E% carbohydrates, 20E% fat)
Number of subjects: 7
Study 12638028 — intervention group
Group type: COMPARATOR
Intervention: High-fat (HF) diet (40E% carbohydrates, 45E% fat)
Number of subjects: 7
Study 12638028 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal intake at various times (0800, 1200, 0400, 1600, 2000, 0000 h)
Number of subjects: 7
Study 12638028 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial increase of pancreatic polypeptide (PP)
Number of subjects: 7
Study 12638028 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine responses (glucagon, TSH, fT4, tT3, cortisol, CgA, PP)
Number of subjects: 7
Study 11094863 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein, very low-calorie diet (VLCD; protein intake 1.5 to 2.0 g/kg of ideal body weight per day; 800 kcal/d) with weekly 2-hour clinic sessions including nutrition instruction, moderate-intensity exercise, and behavior-modification techniques.
Number of subjects: 11
Study 9549286 — intervention group
Group type: EXPERIMENTAL
Intervention: Endarterectomy (EA) of SFAs with Self‐Expanding Coated Stent (Meadox Passager 6‐10 mm) implantation
Number of subjects: 4
Study 9549286 — intervention group
Group type: EXPERIMENTAL
Intervention: Endarterectomy (EA) of SFAs with a 5 mm diameter thin‐walled PTFE endoluminal graft using a Strecker stent for distal fixation
Number of subjects: 4
Study 8230016 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive exercise
Number of subjects: 5
Study 8230016 — intervention group
Group type: COMPARATOR
Intervention: Nonresistive exercise
Number of subjects: 5
Study 3086721 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg of penicillin V potassium twice daily
Number of subjects: 215
Study 3086721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 31441895 — intervention group
Group type: EXPERIMENTAL
Intervention: Juglandis semen complex extract (JCE) 1000 mg
Number of subjects: 0
Study 31441895 — intervention group
Group type: EXPERIMENTAL
Intervention: Juglandis semen complex extract (JCE) 2000 mg
Number of subjects: 0
Study 31441895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27742871 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (400 µg)
Number of subjects: 720
Study 27742871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 720
Study 25684164 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet treatment (126 participants)
Number of subjects: 250
Study 25684164 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulant treatment (124 participants)
Number of subjects: 250
Study 25684164 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet treatment (101 participants, per-protocol analysis)
Number of subjects: 250
Study 25684164 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulant treatment (96 participants, per-protocol analysis)
Number of subjects: 250
Study 23834479 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 268
Study 23834479 — intervention group
Group type: COMPARATOR
Intervention: Cinacalcet plus low-dose vitamin D
Number of subjects: 268
Study 21962214 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (500 mg/kg)
Number of subjects: 3493
Study 21962214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3493
Study 19522023 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 60
Study 19522023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17591349 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health workers (CHWs) intervention including health education, identification, and referral of sick newborns.
Number of subjects: 0
Study 15533561 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharyngeal flap
Number of subjects: 70
Study 15533561 — intervention group
Group type: COMPARATOR
Intervention: Sphincter pharyngoplasty
Number of subjects: 70
Study 11389271 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-impregnated dressing (Biopatch Antimicrobial Dressing)
Number of subjects: 705
Study 11389271 — intervention group
Group type: COMPARATOR
Intervention: 10% povidone-iodine (PI) skin scrub
Number of subjects: 705
Study 10193284 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐emptive local anaesthetic block using 0.5% bupivacaine, together with i.v. tenoxicam and alfentanil
Number of subjects: 32
Study 10193284 — intervention group
Group type: COMPARATOR
Intervention: Postoperative administration of analgesia
Number of subjects: 32
Study 7880351 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical Catheter System (OCS)
Number of subjects: 50
Study 3207528 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fentanyl anaesthesia
Number of subjects: 0
Study 3207528 — intervention group
Group type: COMPARATOR
Intervention: High-dose fentanyl anaesthesia
Number of subjects: 0
Study 29447769 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 7391
Study 29447769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7391
Study 28679435 — intervention group
Group type: EXPERIMENTAL
Intervention: Light physical activity of healthy weight fathers at age 3.5 years
Number of subjects: 0
Study 28679435 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate/vigorous physical activity of fathers at age 5 years
Number of subjects: 0
Study 28679435 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity levels of fathers and children at age 20 months
Number of subjects: 0
Study 25701437 — intervention group
Group type: EXPERIMENTAL
Intervention: Online program consisting of four interactive modules for communication skills training.
Number of subjects: 0
Study 23550526 — intervention group
Group type: EXPERIMENTAL
Intervention: New Beginnings program (attachment-based group intervention)
Number of subjects: 163
Study 23550526 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 163
Study 22048557 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on self-efficacy theory
Number of subjects: 110
Study 22048557 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 110
Study 22048557 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 110
Study 19622687 — intervention group
Group type: COMPARATOR
Intervention: EEG spectral power in alpha2, delta, and theta bands
Number of subjects: 28
Study 19622687 — intervention group
Group type: COMPARATOR
Intervention: EEG spectral power in alpha1, alpha2, delta, and theta bands
Number of subjects: 28
Study 16470086 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg oral magnesium oxide daily
Number of subjects: 22